Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Activity Study of Bevacizumab With Temozolomide Irinotecan for Neuroblastoma in Children

(irinotecan or topotecan) increase the effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This question has been completed. does the addition of dinutuximab beta added to a

temozolomide
filgrastim
shortening fraction
topotecan
metastasis
  • 57 views
  • 24 Jan, 2021
  • 10 locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (R4 randomization - isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba

filgrastim
carboplatin
metastatic neuroblastoma
topotecan
busulfan
  • 288 views
  • 26 Jan, 2021
  • 126 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

stem cell transplantation
carboplatin
shortening fraction
ganglioneuroblastoma
topotecan
  • 66 views
  • 31 Mar, 2021
  • 99 locations
MIBG With Dinutuximab +/- Vorinostat

-MIBG will be given in combination with dinutuximab, a chimeric 14.18 monoclonal antibody. This study will utilize a traditional Phase I rolling 6 dose escalation design to determine a recommended phase

vorinostat
bone marrow procedure
monoclonal antibody ch14.18
monoclonal antibodies
ganglioneuroblastoma
  • 38 views
  • 29 Jan, 2021
  • 11 locations
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology. A promising way to further improve outcome in this disease appears to be the development of adjuvant therapeutic strategies. In this research the anti-GD2 antibody, which is a standard treatment, is to …

bone marrow procedure
neutrophil count
monoclonal antibody ch14.18
shortening fraction
avid
  • 10 views
  • 26 Jan, 2021
  • 3 locations
Treatment With Dinutuximab Sargramostim (GM-CSF) and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

This phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk

  • 0 views
  • 30 Mar, 2021
  • 17 locations
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1

high-risk neuroblastoma
dinutuximab
  • 0 views
  • 05 Apr, 2021
  • 14 locations